Page last updated: 2024-11-07

1-o-hexadecyl-2-n-methylcarbamol -sn-glycerol-3-phosphocholine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

1-O-hexadecyl-2-N-methylcarbamol -sn-glycerol-3-phosphocholine: PAF analog found in rabbit cornea; induces collagenase expression in corneal epithelial cells [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID124663
CHEMBL ID1599651
SCHEMBL ID5501409
MeSH IDM0221642

Synonyms (34)

Synonym
L120 ,
[(2r)-3-hexadecoxy-2-(methylcarbamoyloxy)propyl] 2-trimethylazaniumylethyl phosphate
mc-paf
methylcarbamyl paf
methyl-carbamyl platelet-activating factor
gtpl3427
NCGC00161384-01
NCGC00161384-02
NCGC00161384-03
HMS1989A04
methylcarbamol
c-paf
BML3-F03
[(2r)-3-hexadecoxy-2-(methylcarbamoyloxy)propyl] 2-(trimethylazaniumyl)ethyl phosphate
HMS1361A04
HMS1791A04
91575-58-5
4,7,9-trioxo-2-aza-8-phosphaundecan-11-aminium, 5-((hexadecyloxy)methyl)-8-hydroxy-n,n,n-trimethyl-3-oxo-, hydroxide, inner salt, 8-oxide, (r)-
5-((hexadecyloxy)methyl)-8-hydroxy-n,n,n-trimethyl-3-oxo-4,7,9-trioxo-2-aza-8-phosphaundecan-11-aminium hydroxide, inner salt, 8-oxide, (r)-
1-o-hexadecyl-2-n-methylcarbamol -sn-glycerol-3-phosphocholine
cpaf
mcplatelet activating factor
c-paf (carbamyl-paf )
SCHEMBL5501409
CHEMBL1599651
1-o-hexadecyl-2-n-methylcarbamyl-sn-glycero-3-phosphocholine
1-o-hexadecyl-2-o-(n-methylcarbamoyl)-sn-glyceryl-3-phosphorylcholine
methylcarbamyl paf c-16
HMS3402A04
HMS3648P12
AKOS027379118
1-o-palmitol-2-(n-methylcarbamyl)-sn-glycero-3-phospho-choline
Q27085367
(r)-3-(hexadecyloxy)-2-(methylcarbamoyloxy)propyl 2-(trimethylammonio)ethyl phosphate
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (5)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, MAJOR APURINIC/APYRIMIDINIC ENDONUCLEASEHomo sapiens (human)Potency4.46680.003245.467312,589.2998AID2517
Chain A, CruzipainTrypanosoma cruziPotency31.62280.002014.677939.8107AID1476
TDP1 proteinHomo sapiens (human)Potency2.64930.000811.382244.6684AID686978; AID686979
regulator of G-protein signaling 4Homo sapiens (human)Potency0.29930.531815.435837.6858AID504845
histone acetyltransferase KAT2A isoform 1Homo sapiens (human)Potency2.81840.251215.843239.8107AID504327
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (4)

Assay IDTitleYearJournalArticle
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID588519A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities2011Antiviral research, Sep, Volume: 91, Issue:3
High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors.
AID540299A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis2010Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21
Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (22)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's7 (31.82)18.2507
2000's6 (27.27)29.6817
2010's7 (31.82)24.3611
2020's2 (9.09)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 11.42

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index11.42 (24.57)
Research Supply Index3.14 (2.92)
Research Growth Index4.56 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (11.42)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other22 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]